Non-small cell lung cancer is a serious and potentially life-threatening disease, particularly when diagnosed at advanced metastatic stages where standard prognoses indicate limited long-term survival. However, the medical outlook has evolved dramatically through the advent of precision targeted therapies, next-generation kinase inhibitors, and advanced immunotherapies, transforming advanced NSCLC into a manageable chronic illness for many patients and significantly extending life expectancy.